University of Groningen, University Medical Center Groningen, Department of Cardiology, Groningen, The Netherlands.
University of Groningen, University Medical Center Groningen, Department of Critical Care, Groningen, The Netherlands.
Int J Cardiol. 2017 Dec 1;248:51-56. doi: 10.1016/j.ijcard.2017.08.027. Epub 2017 Aug 10.
In STEMI patients, success of reperfusion of primary PCI predicts cardiac remodeling and clinical outcome. This success may depend on inflammation. We aimed to investigate the association between inflammation and reperfusion success, left ventricular function and long-term mortality in STEMI patients.
In 376 consecutive STEMI patients of the GIPS-III trial hs-CRP levels were measured at baseline, 2weeks, 7weeks and 4months post-PCI. Myocardial blush grade was used to determine success of myocardial reperfusion. In multivariate models sex, age, hs-CRP levels at baseline, NT-proBNP levels at baseline, ischemia time, heart rate, TIMI flow, and CK, CKMB and troponin AUC were included. Follow-up was complete until 4months.
Baseline hs-CRP levels were 2.1mg/l (IQR 0.5-4.2mg/l). hs-CRP levels were associated with impaired reperfusion (OR 1.239, 95% CI 1.006-1.527) and remained higher compared to patients with normal reperfusion up to 2months after PCI (hs-CRP 1.9mg/l (IQR 0.9-3.7mg/l) versus 1.5mg/l (IQR 0.7-2.7mg/l), p=0.041). In multivariate analysis baseline hs-CRP levels remained independently associated with impaired reperfusion. In patients with impaired reperfusion, hs-CRP and NT-proBNP levels remained higher during 4months of follow-up. No correlation was observed between hs-CRP at baseline and left ventricular function at 4months. The number of events was small and we observed no differences in mortality.
Increased hs-CRP levels at presentation are associated with impaired microvascular reperfusion after PCI in STEMI patients and remain higher until 2months follow-up.
在 ST 段抬高型心肌梗死(STEMI)患者中,直接经皮冠状动脉介入治疗(PCI)的再灌注成功预测心脏重构和临床结局。这种成功可能取决于炎症反应。本研究旨在探讨 STEMI 患者炎症反应与再灌注成功、左心室功能和长期死亡率之间的关系。
在 GIPS-III 试验的 376 例连续 STEMI 患者中,在 PCI 后基线、2 周、7 周和 4 个月测量高敏 C 反应蛋白(hs-CRP)水平。心肌灌注分级(MBG)用于确定心肌再灌注的成功程度。在多变量模型中,纳入了性别、年龄、基线 hs-CRP 水平、基线 NT -proBNP 水平、缺血时间、心率、TIMI 血流以及 CK、CKMB 和肌钙蛋白 AUC。随访至 4 个月。
基线 hs-CRP 水平为 2.1mg/L(IQR:0.5-4.2mg/L)。hs-CRP 水平与再灌注不良相关(OR:1.239,95%CI:1.006-1.527),并且直至 PCI 后 2 个月仍高于正常再灌注患者(hs-CRP:1.9mg/L(IQR:0.9-3.7mg/L)比 1.5mg/L(IQR:0.7-2.7mg/L),p=0.041)。多变量分析显示,基线 hs-CRP 水平与再灌注不良独立相关。在再灌注不良的患者中,hs-CRP 和 NT-proBNP 水平在 4 个月的随访期间仍较高。在基线 hs-CRP 水平与 4 个月时的左心室功能之间未观察到相关性。事件数量较少,我们未观察到死亡率的差异。
在 STEMI 患者中,入院时 hs-CRP 水平升高与 PCI 后微血管再灌注不良相关,并且在 2 个月的随访期间仍保持较高水平。